DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,464,286 B2 Zhu Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,464,286 B2 Zhu Et Al USOO9464286B2 (12) United States Patent (10) Patent No.: US 9,464,286 B2 Zhu et al. (45) Date of Patent: Oct. 11, 2016 (54) HIGH THROUGHPUT GENERATION AND 5,767,260 A 6/1998 Whitlow et al. AFFINITY MATURATION OF HUMANIZED 5,780,279 A 7/1998 Matthews et al. 5,798,208 A 8, 1998 Crea ANTIBODY 5,811,238 A 9, 1998 Stemmer et al. 5,814,476 A 9, 1998 Kauffman et al. (75) Inventors: Li Zhu, Palo Alto, CA (US); 5,817483. A 10, 1998 Kauffman et al. Shuanghong Wei, San Jose, CA (US); 5,821,047 A 10, 1998 Garrard et al. Shaobing B. Hua, Cupertino, CA (US) 5,824,514 A 10, 1998 Kauffman et al. 5,830,663 A 11/1998 Embleton et al. 5,837,242 A 11/1998 Holliger et al. (73) Assignee: Adimab, LLC, Lebanon, NH (US) 5,837,500 A 11/1998 Ladner et al. 5,840,479 A 11/1998 Little et al. (*) Notice: Subject to any disclaimer, the term of this 5,846,765 A 12/1998 Matthews et al. patent is extended or adjusted under 35 5,858,657 A 1/1999 Winter et al. U.S.C. 154(b) by 0 days. 5,858,671 A 1/1999 Jones 5,863,765 A 1/1999 Berry et al. 5,866,344 A 2/1999 Georgiou (21) Appl. No.: 11/480,037 5,869,250 A 2/1999 Cheng et al. 5,871,907 A 2f1999 Winter et al. (22) Filed: Jun. 29, 2006 5,872,215 A 2f1999 Osbourne et al. (65) Prior Publication Data (Continued) US 2006/0246515 A1 Nov. 2, 2006 FOREIGN PATENT DOCUMENTS DE 19624562 A1 1, 1998 Related U.S. Application Data EP O404097 A2 12, 1990 (63) Continuation of application No. 10/460,595, filed on (Continued) Jun. 11, 2003, now abandoned. (60) Provisional application No. 60/403.296, filed on Aug. OTHER PUBLICATIONS 12, 2002. Co et al. Nature, 351:501-502, Jun. 6, 1991.* Fundamental Immunology, William E. Paul, ed., 3rd Edition, 1993, (51) Int. Cl. pp. 292-295.* CI2O I/68 (2006.01) Rudikoff et al. Proc. Natl. Acad. Sci. USA, 7.9:1979-1983, Mar. CI2N IS/10 (2006.01) 1982.* (52) U.S. Cl. Radar et al. Proc. Natl. Acad. Sci. USA, 95:89 10-8915, Jul. 1998.* CPC ....... CI2N 15/1041 (2013.01); CI2N 15/1062 MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.* (2013.01); C12N 15/1086 (2013.01) Casset et al. Biochemical and Biophysical Research Communica (58) Field of Classification Search tions, 307: 198-205, 2003.* None (Continued) See application file for complete search history. (56) References Cited Primary Examiner — Laura B Goddard Assistant Examiner — Meera Natarajan U.S. PATENT DOCUMENTS (74) Attorney, Agent, or Firm — Brenda Herschbach 4,230,685 A 10/1980 Senyei et al. Jarrell; Robert N. Sahr; Choate Hall & Stewart LLP 4,452,773. A 6/1984 Molday 4,661,454. A 4, 1987 Botstein et al. (57) ABSTRACT 4,770,183 A 9, 1988 Groman et al. Compositions, methods, and kits are provided for efficiently 4,816,567 A 3/1989 Cabilly et al. 4.946,778 A 8, 1990 Ladner et al. generating and screening humanized antibody with high 4.959,317 A 9, 1990 Sauer affinity against a specific antigen. The library of humanized 5,118,605 A 6, 1992 Urdea antibody is generated by mutagenizing a chimeric antibody 5,223,409 A 6, 1993 Ladner et al. template that combines human antibody framework and 5,283,173 A 2f1994 Fields et al. 5,380,833. A 1, 1995 Urdea antigen binding sites of a non-human antibody. Alterna 5,506,121 A 4, 1996 Skerra et al. tively, the library of humanized antibody is generated by 5,525.490 A 6, 1996 Erickson et al. grafting essential antigen-recognition segment(s) such as 5.530,101 A * 6/1996 Queen et al. CDRs of the non-human antibody into the corresponding 5,565,332 A 10/1996 Hoogenboom et al. position(s) of each member of a human antibody library. 5,571,698 A 11/1996 Ladner et al. 5,618,920 A 4/1997 Robinson et al. This library of humanized antibody is then screened for high 5,658,727 A 8, 1997 Barbas et al. affinity binding toward a specific antigen in vivo in organism 5,688,666 A 11/1997 Bass et al. Such as yeast or in vitro using techniques such as ribosome 5,695,941 A 12/1997 Brent et al. display or mRNA display. The overall process can be 5,712, 120 A 1/1998 Rodriguez et al. efficiently performed in a high throughput and automated 5,723,323 A 3, 1998 Kauffman et al. 5,723,584 A 3, 1998 Schatz manner, thus mimicking the natural process of antibody 5,733,743 A 3, 1998 Johnson et al. affinity maturation. 5,739,281 A 4, 1998 Thogersen et al. 5,750,373 A 5, 1998 Garrard et al. 18 Claims, 13 Drawing Sheets US 9,464,286 B2 Page 2 (56) References Cited 6,696,248 B1 2/2004 Knappik et al. 6,696.251 B1 2/2004 Wittrup et al. U.S. PATENT DOCUMENTS 6,699.658 B1 3/2004 Wittrup et al. 6,706.484 B1 3/2004 Knappik et al. 5,874,239 A 2, 1999 Schatz 6,750,042 B2 6/2004 Summers et al. 5,885,793 A 3, 1999 Griffiths et al. 6,753,136 B2 6/2004 Lohning 5,888,773 A 3, 1999 Jost et al. 6,806,079 B1 10/2004 McCafferty et al. 5,917,018 A 6/1999 Thogersen et al. 6,828,422 B1 12/2004 Achim et al. 5,922,545 A 7, 1999 Mattheakis et al. 6,833,441 B2 * 12/2004 Wang et al. 5.928,868 A 7, 1999 Liu et al. 6,841,359 B2 1/2005 Szostalk et al. 5933.433. A 8, 1999 Schatz 6,846,634 B1 1/2005 Tomlinson et al. 5,935,831 A 8/1999 Quax et al. 6,916,605 B1 7/2005 McCafferty et al. 5.948,620 A 9, 1999 Hurd et al. 6,919, 183 B2 7/2005 Fandl et al. 5,955,275 A 9, 1999 Kamb et al. 6,969,586 B1 1 1/2005 Lerner et al. 5,962.255. A 10/1999 Griffiths et al. 7,005,503 B2 2/2006 Zhu et al. 5,965,368 A 10, 1999 Vidal et al. 7,037,706 B1 5, 2006 Barrett et al. 5,969.108 A 10/1999 McCafferty et al. 7,063,943 B1 6/2006 McCafferty et al. 5,976,862 A 1 1/1999 Kauffman et al. 7,083,945 B1 8/2006 Chen et al. 5,994,515 A 11/1999 Hoxie 7,094,571 B2 8/2006 Harvey et al. 5,994,519 A 1 1/1999 Osbourn et al. 7,112,439 B2 9/2006 Johnson et al. 6,010,884 A 1/2000 Griffiths et al. 7,118,915 B2 10/2006 Vogt et al. 6,017,732 A 1/2000 Jespers et al. 7,138,253 B2 11/2006 Szostaket al. 6,022,729 A 2/2000 Steinbuchel et al. 7,166.423 B1 1/2007 Miltenyi et al. 6,027,910 A 2/2000 Klis et al. 7,172,877 B2 2/2007 Ting 6,040,136 A 3, 2000 Garrard et al. 7,189,841 B2 3/2007 Lerner et al. 6,057,098 A 5, 2000 Buechler et al. 7,208,293 B2 4/2007 Ladner et al. 6,057.101 A 5/2000 Nandabalan et al. 7,229,757 B2 6/2007 Barrett et al. 6,072,036 A 6/2000 Marasco et al. 7,252.998 B2 8/2007 Skerra et al. 6,072,039 A 6, 2000 Haase et al. 7,282.475 B2 10/2007 Porter et al. 6 oss 693 A 7/2000 Nandabalan et al. 7,302,146 B2 11/2007 Turner et al. 6,03493 A 8, 2000 Skerra et al. 7.315,019 B2 1/2008 Turner et al. 6,114,147 A 9, 2000 Frenken et al. 7.335,019 B2 2/2008 Suzuki et al. 6,132,963 A 10, 2000 Brent et al. 7,355,008 B2 4/2008 Stavenhagen et al. 6,140,471. A 10/2000 Johnson et al. 7,371,849 B2 5/2008 Honda et al. 6,159,705. A 12/2000 Trueheart et al. 7,435,553 B2 10/2008 Fandl et al. 6,171,795 B1 1/2001 Korman et al. 7.465,787 B2 12/2008 Wittrup et al. 6,172,197 B1 1/2001 McCafferty et al. 7,569,357 B2 8/2009 Kranz et al. 6,180,336 B1 1/2001 Osbourn et al. 7,700,302 B2 4/2010 Hua et al. 6,187,535 B1 2, 2001 LeGrain et al. 8,691.225 B2 4/2014 Schoeberl et al. 6,200,759 B1 3, 2001 Dove et al. 8,877,688 B2 11/2014 Vasquez et al. 6,235.447 B1 5/2001 Winteret al. 8,927,694 B2 1/2015 McDonagh et al. 6.248,516 B1 6, 2001 Winter et al. 8,961,966 B2 2/2015 Schoeberl et al. 6,265,552 B 72001 Schatz 2002/0004215 A1 1/2002 Osbourn et al. 6.291,158 B1 9, 2001 Winter et al. 2002fOO69421 A1 6/2002 Hale et al.
Load more

Recommended publications
  • Product Datasheet DHX15 Rnai H00001665
    Product Datasheet DHX15 RNAi H00001665-R02-20nmol Unit Size: 20 nmol Store at -20C. Avoid freeze-thaw cycles. Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/H00001665-R02 Updated 4/25/2019 v.20.1 Earn rewards for product reviews and publications. Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/H00001665-R02 Page 1 of 2 v.20.1 Updated 4/25/2019 H00001665-R02-20nmol DHX15 RNAi Product Information Unit Size 20 nmol Concentration Concentration is not relevant for this product. Please see the protocols for proper use of this product. Storage Store at -20C. Avoid freeze-thaw cycles. Buffer DEPC-treated Water Product Description Gene ID 1665 Gene Symbol DHX15 Species Human Specificity/Sensitivity spondyloepiphyseal dysplasia, late, pseudogene (SEDLP) on chromosome 19 Notes This product is produced by and distributed for Abnova, a company based in Taiwan. Product Application Details Applications RNA Inhibition, RNAi sequence position Recommended Dilutions RNA Inhibition, RNAi sequence position Application Notes This RNAi causes protein knockdown. Novus Biologicals USA Novus Biologicals Canada 10730 E. Briarwood Avenue 461 North Service Road West, Unit B37 Centennial, CO 80112 Oakville, ON L6M 2V5 USA Canada Phone: 303.730.1950 Phone: 905.827.6400 Toll Free: 1.888.506.6887 Toll Free: 855.668.8722 Fax: 303.730.1966 Fax: 905.827.6402 [email protected] [email protected] Novus Biologicals Europe General Contact Information 19 Barton Lane www.novusbio.com Abingdon Science Park Technical Support: [email protected] Abingdon, OX14 3NB, United Kingdom Orders: [email protected] Phone: (44) (0) 1235 529449 General: [email protected] Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 [email protected] Limitations This product is for research use only and is not approved for use in humans or in clinical diagnosis.
    [Show full text]
  • Identification of Biomarker Responses in Humans Under Experimentally Induced Zinc Depletion
    IDENTIFICATION OF BIOMARKER RESPONSES IN HUMANS UNDER EXPERIMENTALLY INDUCED ZINC DEPLETION By MOON-SUHN RYU A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2011 1 © 2011 Moon-Suhn Ryu 2 To my parents, Ji-Chul Ryu and Soon-Young Park, and my grandmother, Jung-Seo Seo 3 ACKNOWLEDGMENTS The achievements from the past years in my life as a doctoral student would not exist without the presence of the support and love from my family far way in South Korea. I thank my parents for their love and belief in me which have been the greatest motivation for me to pursue accomplishments and success with my best efforts. I also render my gratefulness to my younger sister, Jin-Suhn Ryu, for being the best supporter in all aspects of my life. Additionally, I thank everyone with whom I shared the moments in the lab, especially, Dr. Juan P. Liuzzi, Dr. Louis A. Lichten, Dr. Liang Guo, Dr. Shou- mei Chang, Tolunay Beker Aydemir, for their invaluable advices and help. The excitement from our findings was always the greatest motivation for me to stay in progress. I also thank Gregory Guthrie, Alyssa Maki, Luisa Rios and Vanessa Da Silva for their cheer and support, particularly, during the last year of my doctoral research. I thank Meena Shankar and the staff members at the General Clinical Research Center for their advices and assistance during the phases of study design and implementation of the dietary regimen.
    [Show full text]
  • This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. PHENOTYPES AND GENETIC MARKERS OF CANCER CACHEXIA Neil Johns MD Thesis presented to The University of Edinburgh – 2015 Table of Contents Acknowledgements ....................................................................................... i Declaration of originality ............................................................................. iii List of publications arising from this thesis .............................................. iv Abbreviations ................................................................................................ v Abstract ........................................................................................................ xi Chapter 1 – Introduction
    [Show full text]
  • Rabbit Anti-TRAPPC2/FITC Conjugated Antibody
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-TRAPPC2/FITC Conjugated antibody SL16583R-FITC Product Name: Anti-TRAPPC2/FITC Chinese Name: FITC标记的SEDL蛋白抗体 hYP38334; MBP 1 interacting protein 2A; MBP-1-interacting protein 2A; MIP 2A; MIP-2A; MIP2A; SEDL; Sedlin; SEDLP; SEDT; Spondyloepiphyseal dysplasia tarda Alias: protein; Spondyloepiphyseal dysplasia, late; TPC2A_HUMAN; Trafficking protein particle complex 2; Trafficking protein particle complex subunit 2; TRAPPC2P1; TRS20; ZNF547L. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Dog,Cow,Rabbit,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 16kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human TRAPPC2 Lsotype: IgGwww.sunlongbiotech.com Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: The protein encoded by this gene is thought to be part of a large multi-subunit complex involved in the targeting and fusion of endoplasmic reticulum-to-Golgi transport Product Detail: vesicles with their acceptor compartment.
    [Show full text]
  • Supplemental Table 1A. Differential Gene Expression Profile of Adehcd40l and Adehnull Treated Cells Vs Untreated Cells
    Supplemental Table 1a. Differential Gene Expression Profile of AdEHCD40L and AdEHNull treated cells vs Untreated Cells Fold change Regulation Fold change Regulation ([AdEHCD40L] vs ([AdEHCD40L] ([AdEHNull] vs ([AdEHNull] vs Probe Set ID [Untreated]) vs [Untreated]) [Untreated]) [Untreated]) Gene Symbol Gene Title RefSeq Transcript ID NM_001039468 /// NM_001039469 /// NM_004954 /// 203942_s_at 2.02 down 1.00 down MARK2 MAP/microtubule affinity-regulating kinase 2 NM_017490 217985_s_at 2.09 down 1.00 down BAZ1A fibroblastbromodomain growth adjacent factor receptorto zinc finger 2 (bacteria-expressed domain, 1A kinase, keratinocyte NM_013448 /// NM_182648 growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer 203638_s_at 2.10 down 1.01 down FGFR2 syndrome, Jackson-Weiss syndrome) NM_000141 /// NM_022970 1570445_a_at 2.07 down 1.01 down LOC643201 hypothetical protein LOC643201 XM_001716444 /// XM_001717933 /// XM_932161 231763_at 3.05 down 1.02 down POLR3A polymerase (RNA) III (DNA directed) polypeptide A, 155kDa NM_007055 1555368_x_at 2.08 down 1.04 down ZNF479 zinc finger protein 479 NM_033273 /// XM_001714591 /// XM_001719979 241627_x_at 2.15 down 1.05 down FLJ10357 hypothetical protein FLJ10357 NM_018071 223208_at 2.17 down 1.06 down KCTD10 potassium channel tetramerisation domain containing 10 NM_031954 219923_at 2.09 down 1.07 down TRIM45 tripartite motif-containing 45 NM_025188 242772_x_at 2.03 down 1.07 down Transcribed locus 233019_at 2.19 down 1.08 down CNOT7 CCR4-NOT transcription complex, subunit 7 NM_013354
    [Show full text]
  • Thesis Sci 2006 Karreman Rj (1).Pdf
    The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non- commercial research purposes only. Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author. University of Cape Town THE LOCALIZATION, FUNCTION AND APPLICATIONS OF THE STRESS RESPONSE PROTEIN HSP12P IN THE YEAST SACCHAROMYCES CEREVISIAE. by Robert Jan Karreman Town Cape A thesis submittedof for the degree of Doctor of Philosophy in the Department of Molecular and Cell Biology, Faculty of Science University of Cape Town, South Africa. University March 2006 PREFACE The work presented in this thesis was perfonned under the supervision of Associate Professors George G. Lindsey and WolfF. Brandt at the Department of Molecular and Cell Biology, University of Cape Town, South Africa. I hereby declare that this thesis, submitted for the degree of Doctor of Philosophy in Molecular and Cell Biology at the University of Cape Town, is the result of my own investigation, except where the work of others is acknowledged. Robert Jan Karreman University of Cape Town March 2006 University of Cape Town ACKNOWLEDGEMENTS [ would like to thank the following people and/or organizations: My supervisor, George Lindsey, for being an excellent and understanding mentor. My parents, "Rube" Karreman and Louise Karreman, for all their dedication, love and support throughout my studies with special thanks to my dad for all the time on the MS.
    [Show full text]
  • Program Nr: 1 from the 1999 ASHG Annual Meeting Development of a Strategy to Screen for Mutations and Drugs Affecting Gene Expre
    Program Nr: 1 from the 1999 ASHG Annual Meeting Development of a strategy to screen for mutations and drugs affecting gene expression and its application to genomic imprinting. A.L. Beaudet, T.-F. Tsai, K.-S. Chen, J. Weber, M. Justice. Dept Molecular & Human Gen, Baylor Col Medicine, Houston, TX. We wished to isolate mutations affecting genomic imprinting related to Prader Willi and Angelman syndrome. We used the mouse Snrpn promoter which lies within a CpG island that is methylated and silenced on the maternal chromosome as opposed to unmethylated and expressed on the paternal chromosome. In ES cells, we introduced the agouti cDNA as a knockin gene under the control of the Snrpn promoter. In nonagouti (a/a) mice, paternal inheritance of the fusion gene confers a tannish abdominal color; the abdomen is black if the fusion gene is absent or inherited maternally. Differential methylation and imprinted expression of the Snrpn promoter was preserved and switched normally, and administration of 5-azacytidine altered coat color. Two breeding strategies involving ENU mutagenesis of males were utilized: (1) males homozygous for the fusion gene and a/a were mutagenized and bred to a/a wild type females to yield 100 percent tannish offspring and (2) mutagenized wild type a/a males were bred to females a/a and homozygous for the fusion gene to yield 100 percent black offspring, such that mutations affecting genomic imprinting could be detected visually. No mutant animals were isolated in the first >100 offspring from breeding scheme 1 and one presumptive mutation or epigenetic event affecting imprinting and causing an unmethylated maternal allele was found in the first >150 animals from breeding scheme 2.
    [Show full text]
  • Affymetrix Probe ID Gene Symbol 1007 S at DDR1 1494 F At
    Affymetrix Probe ID Gene Symbol 1007_s_at DDR1 1494_f_at CYP2A6 1552312_a_at MFAP3 1552368_at CTCFL 1552396_at SPINLW1 /// WFDC6 1552474_a_at GAMT 1552486_s_at LACTB 1552586_at TRPV3 1552619_a_at ANLN 1552628_a_at HERPUD2 1552680_a_at CASC5 1552928_s_at MAP3K7IP3 1552978_a_at SCAMP1 1553099_at TIGD1 1553106_at C5orf24 1553530_a_at ITGB1 1553997_a_at ASPHD1 1554127_s_at MSRB3 1554152_a_at OGDH 1554168_a_at SH3KBP1 1554217_a_at CCDC132 1554279_a_at TRMT2B 1554334_a_at DNAJA4 1554480_a_at ARMC10 1554510_s_at GHITM 1554524_a_at OLFM3 1554600_s_at LMNA 1555021_a_at SCARF1 1555058_a_at LPGAT1 1555197_a_at C21orf58 1555282_a_at PPARGC1B 1555460_a_at SLC39A6 1555559_s_at USP25 1555564_a_at CFI 1555594_a_at MBNL1 1555729_a_at CD209 1555733_s_at AP1S3 1555906_s_at C3orf23 1555945_s_at FAM120A 1555947_at FAM120A 1555950_a_at CD55 1557137_at TMEM17 1557910_at HSP90AB1 1558027_s_at PRKAB2 1558680_s_at PDE1A 1559136_s_at FLJ44451 /// IDS 1559490_at LRCH3 1562378_s_at PROM2 1562443_at RLBP1L2 1563522_at DDX10 /// LOC401533 1563834_a_at C1orf62 1566509_s_at FBXO9 1567214_a_at PNN 1568678_s_at FGFR1OP 1569629_x_atLOC389906 /// LOC441528 /// LOC728687 /// LOC729162 1598_g_at GAS6 /// LOC100133684 200064_at HSP90AB1 200596_s_at EIF3A 200597_at EIF3A 200604_s_at PRKAR1A 200621_at CSRP1 200638_s_at YWHAZ 200640_at YWHAZ 200641_s_at YWHAZ 200702_s_at DDX24 200742_s_at TPP1 200747_s_at NUMA1 200762_at DPYSL2 200872_at S100A10 200878_at EPAS1 200931_s_at VCL 200965_s_at ABLIM1 200998_s_at CKAP4 201019_s_at EIF1AP1 /// EIF1AX 201028_s_at CD99 201036_s_at HADH
    [Show full text]
  • Supporting Information
    Supporting Information Ryu et al. 10.1073/pnas.1117207108 SI Text water. Consistency of measurements was monitored with a refer- SI Materials and Methods. Human subjects. Male subjects 21–35 y of ence zinc standard (0.6 mg Zn∕L). age, weighing at least 50 kg, were recruited to participate. Details PBMC and circulating erythroid cells (erythrocytes and reticu- of the subject characteristics and exclusion criteria are provided locytes) were fractionated from whole blood collected in Vacutai- in Table S1. The study was approved by both the Institutional ner tubes pretreated with K3 EDTA. For PBMC isolation, 9 mL Review Board and the Clinical Research Center of the University of whole blood was placed on an equal vol of Histopaque 1077 of Florida. All subjects provided written informed consent prior (Sigma) and centrifuged at 400 × g × 30 min at room tempera- to enrollment. The study was registered at clinicaltrials.gov as ture. The PBMC layer was collected and washed with PBS at NCT01221129. 250 × g × 10 min, twice. Recovered PBMCs were treated with 1 mL of TRI reagent for RNA isolation. The RBC pellet was Acute dietary zinc depletion. The design was a 24-d study comprised diluted with 1 volume of PBS was stored at 4 °C until processed of three phases of dietary treatment (Fig. 1A). Each subject for reticulocyte RNA preparation. served as their own control. In order to establish a defined base- Remnant erythroid cells from the PBMC isolation procedure (with 9 mL of whole blood) were processed to yield a reticulocyte line condition (acclimation) prior to dietary zinc depletion, sub- RNA preparation.
    [Show full text]
  • Final Thesis Version-20101220
    STUDY OF OSTEOSARCOMA DEVELOPMENT, PROGRESSION AND TREATMENT 1. Gene Profiling and Tumorigenesis 2. IGF-1R/MEK/ERK Signalling and Malignant Potential 3. IGF-1R Targeted Therapy Enhances Chemotherapy Using Doxorubicin CHEUK FAI FREDERICK LUK A thesis presented in fulfilment of the requirements for the degree of Doctor of Philosophy Prince of Wales Clinical School Faculty of Medicine University of New South Wales Sydney, Australia August, 2010 i Copyright Statement ‘I hereby grant the University of New South Wales or its agents the right to archive and to make available my thesis or dissertation in whole or part in the University libraries in all forms of media, now or here after known, subject to the provisions of the Copyright Act 1968. I retain all proprietary rights, such as patent rights. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation. I also authorise University Microfilms to use the 350 word abstract of my thesis in Dissertation Abstract International (this is applicable to doctoral theses only). I have either used no substantial portions of copyright material in my thesis or I have obtained permission to use copyright material; where permission has not been granted I have applied/will apply for a partial restriction of the digital copy of my thesis or dissertation.' Signed: _______________________________________ 14th December 2010 Dated: _______________________________________ Authenticity Statement ‘I certify that the Library deposit digital copy is a direct
    [Show full text]
  • Noncanonical and Canonical Splice Sites
    European Journal of Human Genetics (2009) 17, 510 – 516 & 2009 Macmillan Publishers Limited All rights reserved 1018-4813/09 $32.00 www.nature.com/ejhg ARTICLE Noncanonical and canonical splice sites: a novel mutation at the rare noncanonical splice-donor cut site (IVS4 þ 1A4G) of SEDL causes variable splicing isoforms in X-linked spondyloepiphyseal dysplasia tarda Feng Xiong1,8, Jianjun Gao*,2,3,4,8, Jun Li2, Yun Liu4, Guoyin Feng2, Wenli Fang3, Hongfen Chang3, Jiang Xie1, Haitao Zheng5, Tingyu Li*,1 and Lin He*,2,6,7 1Children’s Hospital of Chongqing Medical University, Central District, Chongqing, PR China; 2Bio-X Center, Shanghai Jiao Tong University, Shanghai, China; 3Changning Greenland Hospital, Institute for Neuropsychiatric Science and Metabonomics, Shanghai Jiao Tong University, Shanghai, China; 4Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Graduate School of Chinese Academy Sciences, Shanghai, China; 5Department of Abdominal Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, Shangdong Province, China; 6The Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China; 7Institutes of Biomedical Sciences, Fudan University, Shanghai, China X-linked spondyloepiphyseal dysplasia tarda can be caused by mutations in the SEDL gene. This study describes an interesting novel mutation (IVS4 þ 1A4G) located exactly at the rare noncanonical AT–AC consensus splicing donor point of SEDL, which regained the canonical GT–AG consensus splicing junction in addition to several other rarer noncanonical splice patterns. The mutation activated several cryptic splice sites and generated the production of seven erroneous splicing isoforms, which we confirmed by sequencing of RT-PCR products and resequencing of cDNA clones.
    [Show full text]
  • Molecular Markers of Lymph Node Metastases in Oral Cancer
    MOLECULAR MARKERS OF LYMPH NODE METASTASES IN ORAL CANCER Frank Karel Johan Leusink The research in this thesis was performed at the departments of Oral & Maxillofacial Surgery and Pathology, University Medical Center Utrecht, the Netherlands, and at the departments of Pathology and Otolaryngology-Head and Neck Surgery, Section Tumor Biology, VU University Medical Center, Amsterdam, the Netherlands. The research was financially supported by the Dutch Cancer Society (KWF Kankerbestrijding) Grant No. KUN 2006-3675 and by the Dutch Society of Oral & Maxillofacial Surgery (NVMKA) BOOA Research Grant 2009. No commercial funding was received to perform this research. Printed by Gildeprint Layout by Nicole Nijhuis, Gildeprint Cover design Karel J. Leusink | kareljleusink.blogspot.nl ISBN: 978-94-6233-502-8 © Copyright 2016, F.K.J. Leusink All rights reserved. No part of this book may be reproduced in any form, by print, photocopy, electronic data transfer or any other means, without prior permission of the author. MOLECULAR MARKERS OF LYMPH NODE METASTASES IN ORAL CANCER Moleculaire markers voor lymfklier metastasen van mondkanker [met een samenvatting in het Nederlands] Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof. dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 31 januari 2017 des middags 2.30 uur door Frank Karel Johan Leusink geboren 7 april 1979 te Hengelo (O.) Promotoren: Prof. dr. P.J. van Diest Prof. dr. R. Koole Copromotoren: Dr. S.M. Willems Dr. R.J.J. van Es CONTENTS Chapter 1.
    [Show full text]